Clinical evaluation of the CarboMedics prosthesis

Experience at providence health system in Portland

Kenji Minakata, YingXing X. Wu, Kathryn J. Zerr, Gary L. Grunkemeier, John R. Handy, Aftab Ahmad, Albert Starr, Anthony P. Furnary

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and aims of the study: This study details the authors' experience with the CarboMedics bileaflet mechanical prosthesis, and assesses the valve's efficacy in terms of early mortality and long-term morbidity. Methods: Between July 1994 and December 2000, a total of 696 CarboMedics valves was implanted in 616 patients. Aortic valve replacement (AVR) was performed in 350 (57%) patients, mitral valve replacement (MVR) in 161 (26%), double (aortic + mitral) valve replacement (DVR) in 79 (13%), and other procedures in 26 (4%). Results: There were 32 operative deaths. Operative mortality was 4.3% for AVR, 6.8% for MVR, and 7.6% for DVR. Linearized rates for late death were 3.4%/patient-year (pt-yr), 5.5%/pt-yr and 7.7%/pt-yr for AVR, MVR and DVR, respectively. Survival at five years was 80.1% for AVR, 73.0% for MVR, and 64.6% for DVR (p = 0.004). Freedom from reoperation at five years was 97.6% for AVR, 98.1% for MVR, and 94.1% for DVR (p = 0.718); freedom from thromboembolism at five years was 96.3% for AVR, 98.6% for MVR, and 88.3% for DVR (p = 0.04). Linearized rates of late thromboembolism were 0.7%/pt-yr, 0.4%/pt-yr and 2.3%/pt-yr, respectively. Freedom from PVE at five years was 98.4% for AVR, 97.0% for MVR, and 89.7% for the DVR group (p = 0.172). Linearized rates of PVE were 0.5%/pt-yr, 0.9%/pt-yr and 1.8%/pt-yr, respectively. Freedom from anticoagulant-related bleeding at five years was 98.0% in the AVR group, 97.8% in the MVR group, and 88.3% in the DVR group (p

Original languageEnglish (US)
Pages (from-to)844-850
Number of pages7
JournalJournal of Heart Valve Disease
Volume11
Issue number6
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

Prostheses and Implants
Aortic Valve
Mitral Valve
Health
Thromboembolism
Mortality
Reoperation
Anticoagulants
Hemorrhage
Morbidity
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Minakata, K., Wu, Y. X., Zerr, K. J., Grunkemeier, G. L., Handy, J. R., Ahmad, A., ... Furnary, A. P. (2002). Clinical evaluation of the CarboMedics prosthesis: Experience at providence health system in Portland. Journal of Heart Valve Disease, 11(6), 844-850.

Clinical evaluation of the CarboMedics prosthesis : Experience at providence health system in Portland. / Minakata, Kenji; Wu, YingXing X.; Zerr, Kathryn J.; Grunkemeier, Gary L.; Handy, John R.; Ahmad, Aftab; Starr, Albert; Furnary, Anthony P.

In: Journal of Heart Valve Disease, Vol. 11, No. 6, 11.2002, p. 844-850.

Research output: Contribution to journalArticle

Minakata, K, Wu, YX, Zerr, KJ, Grunkemeier, GL, Handy, JR, Ahmad, A, Starr, A & Furnary, AP 2002, 'Clinical evaluation of the CarboMedics prosthesis: Experience at providence health system in Portland', Journal of Heart Valve Disease, vol. 11, no. 6, pp. 844-850.
Minakata K, Wu YX, Zerr KJ, Grunkemeier GL, Handy JR, Ahmad A et al. Clinical evaluation of the CarboMedics prosthesis: Experience at providence health system in Portland. Journal of Heart Valve Disease. 2002 Nov;11(6):844-850.
Minakata, Kenji ; Wu, YingXing X. ; Zerr, Kathryn J. ; Grunkemeier, Gary L. ; Handy, John R. ; Ahmad, Aftab ; Starr, Albert ; Furnary, Anthony P. / Clinical evaluation of the CarboMedics prosthesis : Experience at providence health system in Portland. In: Journal of Heart Valve Disease. 2002 ; Vol. 11, No. 6. pp. 844-850.
@article{c42a2d49c4b34e8394c22ff38eaa9434,
title = "Clinical evaluation of the CarboMedics prosthesis: Experience at providence health system in Portland",
abstract = "Background and aims of the study: This study details the authors' experience with the CarboMedics bileaflet mechanical prosthesis, and assesses the valve's efficacy in terms of early mortality and long-term morbidity. Methods: Between July 1994 and December 2000, a total of 696 CarboMedics valves was implanted in 616 patients. Aortic valve replacement (AVR) was performed in 350 (57{\%}) patients, mitral valve replacement (MVR) in 161 (26{\%}), double (aortic + mitral) valve replacement (DVR) in 79 (13{\%}), and other procedures in 26 (4{\%}). Results: There were 32 operative deaths. Operative mortality was 4.3{\%} for AVR, 6.8{\%} for MVR, and 7.6{\%} for DVR. Linearized rates for late death were 3.4{\%}/patient-year (pt-yr), 5.5{\%}/pt-yr and 7.7{\%}/pt-yr for AVR, MVR and DVR, respectively. Survival at five years was 80.1{\%} for AVR, 73.0{\%} for MVR, and 64.6{\%} for DVR (p = 0.004). Freedom from reoperation at five years was 97.6{\%} for AVR, 98.1{\%} for MVR, and 94.1{\%} for DVR (p = 0.718); freedom from thromboembolism at five years was 96.3{\%} for AVR, 98.6{\%} for MVR, and 88.3{\%} for DVR (p = 0.04). Linearized rates of late thromboembolism were 0.7{\%}/pt-yr, 0.4{\%}/pt-yr and 2.3{\%}/pt-yr, respectively. Freedom from PVE at five years was 98.4{\%} for AVR, 97.0{\%} for MVR, and 89.7{\%} for the DVR group (p = 0.172). Linearized rates of PVE were 0.5{\%}/pt-yr, 0.9{\%}/pt-yr and 1.8{\%}/pt-yr, respectively. Freedom from anticoagulant-related bleeding at five years was 98.0{\%} in the AVR group, 97.8{\%} in the MVR group, and 88.3{\%} in the DVR group (p",
author = "Kenji Minakata and Wu, {YingXing X.} and Zerr, {Kathryn J.} and Grunkemeier, {Gary L.} and Handy, {John R.} and Aftab Ahmad and Albert Starr and Furnary, {Anthony P.}",
year = "2002",
month = "11",
language = "English (US)",
volume = "11",
pages = "844--850",
journal = "The Journal of heart valve disease",
issn = "0966-8519",
publisher = "ICR Publishers Ltd",
number = "6",

}

TY - JOUR

T1 - Clinical evaluation of the CarboMedics prosthesis

T2 - Experience at providence health system in Portland

AU - Minakata, Kenji

AU - Wu, YingXing X.

AU - Zerr, Kathryn J.

AU - Grunkemeier, Gary L.

AU - Handy, John R.

AU - Ahmad, Aftab

AU - Starr, Albert

AU - Furnary, Anthony P.

PY - 2002/11

Y1 - 2002/11

N2 - Background and aims of the study: This study details the authors' experience with the CarboMedics bileaflet mechanical prosthesis, and assesses the valve's efficacy in terms of early mortality and long-term morbidity. Methods: Between July 1994 and December 2000, a total of 696 CarboMedics valves was implanted in 616 patients. Aortic valve replacement (AVR) was performed in 350 (57%) patients, mitral valve replacement (MVR) in 161 (26%), double (aortic + mitral) valve replacement (DVR) in 79 (13%), and other procedures in 26 (4%). Results: There were 32 operative deaths. Operative mortality was 4.3% for AVR, 6.8% for MVR, and 7.6% for DVR. Linearized rates for late death were 3.4%/patient-year (pt-yr), 5.5%/pt-yr and 7.7%/pt-yr for AVR, MVR and DVR, respectively. Survival at five years was 80.1% for AVR, 73.0% for MVR, and 64.6% for DVR (p = 0.004). Freedom from reoperation at five years was 97.6% for AVR, 98.1% for MVR, and 94.1% for DVR (p = 0.718); freedom from thromboembolism at five years was 96.3% for AVR, 98.6% for MVR, and 88.3% for DVR (p = 0.04). Linearized rates of late thromboembolism were 0.7%/pt-yr, 0.4%/pt-yr and 2.3%/pt-yr, respectively. Freedom from PVE at five years was 98.4% for AVR, 97.0% for MVR, and 89.7% for the DVR group (p = 0.172). Linearized rates of PVE were 0.5%/pt-yr, 0.9%/pt-yr and 1.8%/pt-yr, respectively. Freedom from anticoagulant-related bleeding at five years was 98.0% in the AVR group, 97.8% in the MVR group, and 88.3% in the DVR group (p

AB - Background and aims of the study: This study details the authors' experience with the CarboMedics bileaflet mechanical prosthesis, and assesses the valve's efficacy in terms of early mortality and long-term morbidity. Methods: Between July 1994 and December 2000, a total of 696 CarboMedics valves was implanted in 616 patients. Aortic valve replacement (AVR) was performed in 350 (57%) patients, mitral valve replacement (MVR) in 161 (26%), double (aortic + mitral) valve replacement (DVR) in 79 (13%), and other procedures in 26 (4%). Results: There were 32 operative deaths. Operative mortality was 4.3% for AVR, 6.8% for MVR, and 7.6% for DVR. Linearized rates for late death were 3.4%/patient-year (pt-yr), 5.5%/pt-yr and 7.7%/pt-yr for AVR, MVR and DVR, respectively. Survival at five years was 80.1% for AVR, 73.0% for MVR, and 64.6% for DVR (p = 0.004). Freedom from reoperation at five years was 97.6% for AVR, 98.1% for MVR, and 94.1% for DVR (p = 0.718); freedom from thromboembolism at five years was 96.3% for AVR, 98.6% for MVR, and 88.3% for DVR (p = 0.04). Linearized rates of late thromboembolism were 0.7%/pt-yr, 0.4%/pt-yr and 2.3%/pt-yr, respectively. Freedom from PVE at five years was 98.4% for AVR, 97.0% for MVR, and 89.7% for the DVR group (p = 0.172). Linearized rates of PVE were 0.5%/pt-yr, 0.9%/pt-yr and 1.8%/pt-yr, respectively. Freedom from anticoagulant-related bleeding at five years was 98.0% in the AVR group, 97.8% in the MVR group, and 88.3% in the DVR group (p

UR - http://www.scopus.com/inward/record.url?scp=0036855461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036855461&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 844

EP - 850

JO - The Journal of heart valve disease

JF - The Journal of heart valve disease

SN - 0966-8519

IS - 6

ER -